Curaleaf Holdings reported first quarter 2026 revenue of $324 million, a 6% increase year-over-year, driven by 2% domestic and 35% international growth. The company achieved a gross profit margin of 49% and net income of $70 million, reflecting strong operational performance despite some margin pressure. Curaleaf expanded its retail footprint in key U.S. states and completed the full acquisition of its German subsidiary, Four 20 Pharma. The company also filed for DEA registration, positioning itself for growth following recent regulatory changes in medical cannabis. Curaleaf's strategic investments and new product launches support its outlook for continued industry leadership.
Warner Bros. Discovery's stock fell 4% following a court decision to pause the $110 billion merger deal between Paramount and Skydance. The judge's intervention raises uncertainty about the future of this major entertainment industry consolidation. I...
The CLARITY Act, a key bill aimed at providing clear federal guidelines for digital assets, is facing a vote shortfall in the Senate with only about 51 confirmed or likely yes votes, below the 60 needed. Republican support remains strong, but Democra...
Bitcoin faces a potential drop to $45,000 by early October 2026, linked to patterns seen in past crypto exchange failures like Mt. Gox and FTX. The planned shutdown of BitMEX signals a possible market capitulation phase, with Bitcoin trading near key...
XRP's exchange activity on Binance has sharply declined, dropping from about 650,000 to 350,000 deposits and withdrawals, signaling reduced selling pressure and increased holding. Meanwhile, the NVT Ratio surged, indicating XRP's market value is grow...
Prediction markets on Kalshi assign a 59% probability that XRP will trade below $1 before the end of 2026, reflecting weakened confidence in a sustained recovery despite a recent modest rebound. XRP has struggled to maintain momentum, repeatedly movi...
